Centrus Energy Corp.
LEU
$159.38
+2.13%
Centrus Energy Corp. supplies nuclear fuel and services to the nuclear power industry, operating through Low-Enriched Uranium (LEU) and Technical Solutions segments. As a key U.S. supplier of LEU, it holds a strategic position in the domestic nuclear fuel cycle, benefiting from policy support for domestic enrichment. The current investor narrative centers on the AI-driven energy boom and nuclear renaissance, with recent news highlighting a long-term fuel supply agreement with Oklo and structural uranium supply deficits, though execution risks and Russian contract expirations remain debated.…
LEU
Centrus Energy Corp.
$159.38
Related headlines
Investment Opinion: Should I buy LEU Today?
Rating: Hold. The thesis is that Centrus Energy's strategic position in the U.S. nuclear fuel cycle is valuable, but current valuation and margin headwinds limit upside. Analyst consensus is neutral (2 Buys, 4 Neutrals), with an average EPS estimate of $3.64 for the next fiscal year, implying a forward PE of 47x at the current price.
Supporting evidence: The trailing PE of 56.06x is above the median of recent quarters, indicating the stock is not cheap. Revenue growth has been negative (-3.56% YoY), and gross margin has compressed significantly. Free cash flow TTM is positive at $31.3M, but Q4 FCF was negative. The company has a strong balance sheet with a current ratio of 5.59. Compared to the industry, the stock trades at a premium on earnings and sales, reflecting its strategic premium.
Risks & Conditions: The biggest risks are margin compression, Russian contract expiration, and failure to grow revenue. This Hold would upgrade to Buy if the stock pulls back to a PE below 30x (around $109) or if gross margins stabilize above 30%. It would downgrade to Sell if revenue growth turns negative for two consecutive quarters or if the Russian supply chain is disrupted. Overall, the stock appears overvalued relative to its recent financial performance, but fairly valued given its strategic importance.
Sign up to view all
LEU 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Centrus Energy has a compelling strategic narrative as a key U.S. nuclear fuel supplier, but the financial data shows deteriorating margins and revenue volatility. The stock's high valuation multiples leave little room for error. The neutral stance reflects the balance between long-term structural tailwinds and near-term execution risks. An upgrade to bullish would require evidence of margin stabilization and revenue acceleration, while a downgrade to bearish would follow a significant contract loss or continued margin erosion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centrus Energy Corp.'s 12-month outlook, with a consensus price target around $207.19 and implied upside of +30.0% versus the current price.
Average Target
$207.19
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$128 - $207
Analyst target range
Six analysts cover Centrus Energy, with a consensus leaning neutral. Ratings include 2 Buys (B. Riley, Needham) and 4 Neutrals (UBS, Citigroup, JP Morgan, Roth Capital). The average estimated EPS for the next fiscal year is $3.64, with a range of $3.42 to $3.85. The average revenue estimate is $589M, with a range of $562M to $616M. No explicit price targets are provided, but the EPS estimates imply a forward PE of 47x at the current price, suggesting limited upside if the market maintains current multiples. The wide range of EPS estimates ($3.42-$3.85) indicates moderate uncertainty. Recent analyst actions have been mostly neutral, with no upgrades or downgrades in the past six months, reflecting a wait-and-see stance. The lack of strong bullish consensus suggests the stock may need a catalyst to break out.
Drowning in data?
Find the real signal!
Bulls vs Bears: LEU Investment Factors
Centrus Energy presents a high-risk, high-reward opportunity. The bull case rests on its unique strategic position in the U.S. nuclear fuel cycle, strong liquidity, and structural tailwinds from AI-driven energy demand and the nuclear renaissance. The bear case highlights severe margin compression, elevated valuation multiples, revenue volatility, and dependence on Russian supply contracts. Currently, the bearish evidence is stronger due to deteriorating margins and a stock that has declined 63% from its 52-week high, reflecting market skepticism. The single most important tension is whether the company can convert its strategic positioning into sustainable earnings growth, or if margin pressure and execution risks will continue to erode value.
Bullish
- Strategic Position in Nuclear Renaissance: Centrus is the only U.S.-owned uranium enrichment company, benefiting from policy support for domestic nuclear fuel. The recent long-term fuel supply agreement with Oklo (June 2026) directly addresses a major bottleneck in advanced nuclear, locking in future revenue.
- Strong Liquidity and Cash Position: The company has a current ratio of 5.59 and $1.96B in cash at Q4 2025, providing a substantial cushion for operations and investments. This financial strength reduces bankruptcy risk and enables strategic moves.
- Positive Net Income and ROE: Despite revenue volatility, Centrus remains profitable with net income of $17.8M in Q4 2025 and a trailing ROE of 10.17%. This demonstrates the ability to generate shareholder value even in a cyclical industry.
- Structural Uranium Supply Deficit: AI-driven energy demand is creating a structural uranium supply deficit, as highlighted in recent news. Centrus is well-positioned to capitalize on rising uranium prices and long-term contracts.
Bearish
- Severe Margin Compression: Gross margin fell from 40.77% in Q4 2024 to 23.94% in Q4 2025, and operating margin dropped from 29.75% to 8.76% over the same period. This indicates rising costs or unfavorable product mix, pressuring profitability.
- High Valuation Multiples: Trailing PE of 56.06x and forward PE of 43.38x are elevated, especially given negative earnings growth (PEG ratio -15.73). The PS ratio of 9.72x also implies high growth expectations that may not materialize.
- Revenue Decline and Volatility: Q4 2025 revenue of $146.2M was down 3.56% YoY and declined sequentially from Q2 2025's $154.5M. Revenue has been lumpy, with quarters like Q2 2024 at $189M and Q1 2025 at $73.1M, making forecasting difficult.
- Russian Contract Expiration Risk: A significant portion of Centrus's LEU supply comes from Russian contracts, which are set to expire. Any disruption or failure to renew could severely impact the company's ability to fulfill customer orders and generate revenue.
LEU Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -13.37% and currently trading at $171.05, which is 36.8% of its 52-week range (low $144.65, high $464.25). This positioning near the lower end of the range suggests a potential value opportunity but also reflects persistent selling pressure and a lack of momentum. The stock has underperformed the S&P 500 significantly, with relative strength of -34.0% over the past year. Short-term momentum shows a mixed picture: the 1-month price change is +16.67%, indicating a recent bounce, while the 3-month change is -8.64%, still negative. This divergence suggests a short-term recovery attempt within a longer-term downtrend, which could signal a temporary pullback or early reversal. The stock's beta of 1.359 implies 35.9% more volatility than the market, amplifying both upside and downside moves. Key support is at the 52-week low of $144.65, and resistance at the 52-week high of $464.25. A break below $144.65 would signal further downside, while a move above $464.25 would indicate a trend reversal. The current price is 18.3% above the 52-week low, suggesting some support, but still 63.2% below the high.
Beta
1.36
1.36x market volatility
Max Drawdown
-66.4%
Largest decline past year
52-Week Range
$145-$464
Price range past year
Annual Return
-26.3%
Cumulative gain past year
| Period | LEU Return | S&P 500 |
|---|---|---|
| 1m | -2.0% | +1.4% |
| 3m | -19.4% | +7.4% |
| 6m | -47.9% | +8.6% |
| 1y | -26.3% | +20.3% |
| ytd | -41.5% | +10.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LEU Fundamental Analysis
Revenue has been volatile: Q4 2025 revenue was $146.2M, down 3.56% YoY from $151.6M in Q4 2024, and down from $154.5M in Q2 2025. The trailing twelve-month revenue trend shows deceleration, with Q4 2025 revenue declining sequentially from Q2 2025's $154.5M. The LEU segment, which includes separative work units ($111M) and uranium ($13.4M), drives the majority of revenue. The YoY decline raises concerns about demand timing, though the long-term outlook is supported by nuclear fuel demand. Net income was $17.8M in Q4 2025, down from $53.7M in Q4 2024, but the company remains profitable. Gross margin was 23.94% in Q4 2025, down from 40.77% in Q4 2024, indicating margin compression. Operating margin was 8.76% in Q4 2025, down from 29.75% in the prior year quarter. The decline in margins suggests higher costs or product mix shifts, though the company still generates positive net income. The balance sheet shows a current ratio of 5.59, indicating strong liquidity. Debt-to-equity is 1.59, which is elevated but manageable given the cash position. Free cash flow was -$58M in Q4 2025, but TTM free cash flow was $31.3M. ROE is 10.17%, reflecting decent profitability. The company has $1.96B in cash at end of Q4 2025, providing a cushion for operations and investments.
Quarterly Revenue
$146200000.0B
2025-12
Revenue YoY Growth
-3.6%
YoY Comparison
Gross Margin
23.9%
Latest Quarter
Free Cash Flow
$31300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LEU Overvalued?
Since net income is positive ($17.8M in Q4 2025), the PE ratio is the primary metric. The trailing PE is 56.06x, while the forward PE is 43.38x, implying the market expects earnings growth. The gap between trailing and forward PE suggests an anticipated improvement in earnings, which aligns with analyst estimates of $3.64 EPS for the next fiscal year. Compared to the industry average (not provided, but typically for uranium/energy, PE ratios vary widely), the stock trades at a premium. The PS ratio of 9.72x is high relative to historical levels, indicating the market is pricing in significant future revenue growth. Historically, the trailing PE has ranged from 1.49x (Q4 2021) to 364x (Q3 2025), and the current 56x is above the median of recent quarters, suggesting the stock is not cheap on an earnings basis. The PB ratio of 5.70x is also elevated relative to book value, reflecting the market's premium on the company's strategic position. The PEG ratio is negative (-15.73) due to negative earnings growth expectations, which is a warning sign.
PE
56.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -306x~364x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Centrus faces significant margin compression, with gross margin falling from 40.77% in Q4 2024 to 23.94% in Q4 2025, and operating margin dropping from 29.75% to 8.76%. Revenue is volatile and declined 3.56% YoY in Q4 2025, while free cash flow was negative -$58M in that quarter, though TTM FCF is positive at $31.3M. The debt-to-equity ratio of 1.59 is elevated, but the $1.96B cash position provides a buffer. The company's reliance on Russian supply contracts for LEU is a key operational risk, as expiration could disrupt the supply chain.
Market & Competitive Risks: The stock trades at a trailing PE of 56.06x and forward PE of 43.38x, which is a premium to historical levels and implies high growth expectations. With a beta of 1.359, the stock is 35.9% more volatile than the market, amplifying downside in risk-off environments. The stock has underperformed the S&P 500 by 34% over the past year, reflecting negative sentiment. Competitive threats include other uranium suppliers and the potential for technological disruption in nuclear fuel. Recent news about Oklo's stock slump highlights dilution fears in the sector, which could spill over to Centrus.
Worst-Case Scenario: In a severe downturn, Centrus could face a combination of margin compression, loss of Russian supply contracts, and a broader market sell-off in growth/energy stocks. The realistic downside is to the 52-week low of $144.65, representing a 15.4% decline from the current price of $171.05. However, if the company reports a major earnings miss or contract loss, the stock could fall further, potentially revisiting levels below $100, implying a loss of over 40% from current levels.
FAQ
The key risks are: 1) Margin compression – gross margin fell from 40.77% to 23.94% in the past year, indicating rising costs or unfavorable mix. 2) Russian contract expiration – a significant portion of LEU supply comes from Russia, and failure to renew could disrupt operations. 3) Revenue volatility – quarterly revenue has ranged from $73.1M to $189M, making forecasting difficult. 4) High valuation – the stock trades at a forward PE of 43.38x, leaving little room for error. The most severe risk is a combination of margin compression and contract loss, which could drive the stock to the 52-week low of $144.65 or below.
The 12-month forecast is mixed. In the base case (50% probability), the stock trades in a range of $160-$220, assuming moderate growth and stable margins. In the bull case (20% probability), the stock could reach $250-$350 if the nuclear renaissance accelerates and Centrus secures new contracts. In the bear case (30% probability), the stock could fall to $100-$145 if margins continue to compress or Russian contracts are lost. The most likely scenario is the base case, with the stock near current levels. Key assumptions include analyst EPS estimates of $3.64 and revenue of $589M for the next fiscal year.
LEU appears overvalued based on traditional valuation metrics. The trailing PE of 56.06x and forward PE of 43.38x are well above the historical median, and the PS ratio of 9.72x is high. The PEG ratio is negative (-15.73) due to negative earnings growth expectations, which is a warning sign. Compared to the industry, the stock trades at a premium, reflecting its strategic importance as the only U.S.-owned uranium enricher. However, the market is pricing in significant future growth, which may not materialize given recent revenue declines. The stock is likely overvalued relative to its current financial performance, but could be fairly valued if the nuclear renaissance accelerates.
LEU is a high-risk, high-reward stock. The bull case is supported by its strategic position in the U.S. nuclear fuel cycle, strong liquidity (current ratio 5.59), and structural tailwinds from AI-driven energy demand. However, the stock has declined 63% from its 52-week high, and margins are compressing (gross margin fell from 40.77% to 23.94% YoY). With a forward PE of 43.38x, the stock is priced for perfection. It could be a good buy for aggressive investors who believe in the nuclear renaissance and can tolerate volatility, but it is not suitable for risk-averse investors. The analyst consensus is neutral, with an average EPS estimate of $3.64, implying limited upside at current levels.
LEU is more suitable for long-term investment, given its strategic position in the nuclear fuel cycle and structural tailwinds from AI energy demand. The stock has high volatility (beta 1.359) and has declined 63% from its 52-week high, making it risky for short-term trading. Short-term traders may find opportunities in the stock's 16.67% one-month bounce, but the overall downtrend suggests caution. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the nuclear renaissance thesis to play out. The company does not pay a dividend, so returns depend entirely on price appreciation.
